Prescription Rheumatology Practices Among Mexican Specialists

Archives of Medical Research

Volumn 38, Issue 3, 2007, Pages 354-359

  Goycochea Robles, María Victoria ^a   Arce Salinas, César Alejandro ^b   Guzmán Vázquez, Silvia ^c   Cardiel Ríos, Mario H ^d  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b PEMEX   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^d General Hospital   (Mexico)

Author keywords

Ankylosing spondylitis; Disease modifying anti rheumatic drugs; Drug therapy; Quality of life; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; DISEASE DURATION; DRUG SELF ADMINISTRATION; FEMALE; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL PRACTICE; PRESCRIPTION; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; MEXICO; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PRESCRIPTIONS, DRUG; QUALITY OF LIFE; QUESTIONNAIRES; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

EID: 33847628785     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2006.11.008     Document Type: Article

References (34)

1. Lindqvist E., Saxne T., Geborek P., and Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 61 (2002) 1055-1059
2. Brophy S., Mackay K., Al-Saidi A., Taylor G., and Calin A. The natural history of ankylosing spondylitis as defined by radiological progression. J Rheumatol 29 (2002) 1236-1243
3. Grigor C., Capell H., Stirling A., McMaqhon A.D., Lock P., Vallance R., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004) 263-269
4. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46 (2002) 328-346
5. Choy E.H.S., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344 (2001) 907-916
6. Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Burmester G.R., Bijlsma J.W., et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann Rheum Dis 61 suppl 2 (2002) ii2-ii7
7. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 48 (2003) 1771-1774
8. Keen H.I., and Emery P. How should we manage early rheumatoid arthritis? From imaging to intervention. Curr Opin Rheumatol 17 (2005) 280-285
9. Wanders A., Heijde D., Landewe R., Behier J.M., Calin A., Olivieri I., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52 (2005) 1756-1765
10. Dougados M., Dijkmans B., Khan K., Maksymowych W., van der Linden S.J., and Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 61 suppl III (2002) iii40-iii50
11. Davis J.C., van der Heijde D., Dougados M., and Woolley J.M. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 53 (2005) 494-501
12. Pope J., Hong P., and Koehler B.E. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. J Rheumatol 29 (2002) 255-260
13. Conaghan P.G., Crotty M., Oh E., Day R.O., and Brooks P.M. Antirheumatic drug-prescribing behavior of Australasian rheumatologists 1984-1994. Br J Rheumatol 36 (1997) 487-490
14. Kay E.A., and Pullar T. Variations among rheumatologists in prescribing and monitoring disease modifying anti-rheumatic drugs. Br J Rheumatol 31 (1992) 477-483
15. Blomqvist P., Feltelius N., Ekbom A., and Klareskog L. Rheumatoid arthritis in Sweden. Drug prescriptions, cost and adverse drug reactions. J Rheumatol 27 (2000) 1171-1177
16. Galindo-Rodríguez G., Aviña Zubieta J.A., Fitzgerald A., LeClerq S.A., Russell A.S., and Suárez-Almazor M.E. Variations and trends in the prescription of initial second-line therapy for patients with rheumatoid arthritis. J Rheumatol 24 (1997) 633-638
17. Jobanputra P., Wilson J., Douglas K., and Burls A. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology 43 (2004) 206-210
18. Cardiel M.H., Orozco H., Goycochea V., et al. Cooperative quality of life study of rheumatic diseases in Mexico. Ann Rheum Dis 62 suppl 1 (2003) 75
19. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
20. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., et al., the European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34 (1991) 1218-1227
21. Stucki G., Liang M.H., Stucki S., Bruhlmann P., and Michel B.A. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 38 (1995) 795-798
22. Prevoo M.L.L., Van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B.A., and van Riel P.L.C.M. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
23. Cardiel M.H., Abello-Banfi M., Ruiz-Mercado R., and Alarcón-Segovia D. How to measure health status in rheumatoid arthritis in non-English speaking patients. Validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clin Exp Rheumatol 11 (1993) 117-121
24. Calin A., Garrett S., Whitelock H., Kennedy L.G., O'Hea J., Mallorie P., et al. A new approach to defining functional ability in ankylosing spondylitis: the development of The Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21 (1994) 2281-2285
25. Zúñiga M.A., Carrillo-Jiménez G.T., Fos P.J., Gandek B., and Medina-Moreno M.R. Evaluación del estado de salud con la Encuesta SF-36: resultados preliminares en México. Salud Pub Mex 41 (1999) 110-118
26. Hurst N.P., Kina P., Ruta D., Hunter M., and Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol. Br J Rheumatol 36 (1997) 551-559
27. Keat A., Barkham N., Bhalla A., The BSR Standards, and Guidelines and Audit Working Group. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology 44 (2005) 939-947
28. Boers M., Verhoeven A.C., Markusse H.M., van de Laar M.A., Westhovens R., van Denderen J.C., et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350 (1997) 309-318
29. O'Dell J.R., Leff R., Paulsen G., Haire C., Mallek P., Eckhoff J., et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 1164-1170
30. Calguneri M., Pay S., Caliskaner Z., Apras S., Kiraz S., Ertenli I., and Cobankara V. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 17 (1999) 699-704
31. Browning D.J. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol 133 (2002) 649-656
32. Finbloom D.S., Silver K., Newsome D.A., and Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 12 (1985) 692-694
33. Berard A., Solomon D., and Avorn J. Patterns of drug use in rheumatoid arthritis. J Rheumatol 27 (2000) 1648-1655
34. González I., Carmona L., Balssa A., San Marti R., Belmonte M., Tena X., and The EMECAR Study Group. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol 30 (2003) 697-703